Hudson Bay Capital Management
GALT icon

Hudson Bay Capital Management’s Galectin Therapeutics GALT Stock Holding History

Hudson Bay Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208K Sell
74,728
-3,417
-4% -$10.4K ﹤0.01% 1093
2025
Q4 		$325K Buy
78,145
+63,319
+427% +$333K ﹤0.01% 912
2025
Q3 		$62.8K Buy
+14,826
New +$55.8K ﹤0.01% 1113

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Hudson Bay Capital Management's GALT Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Galectin Therapeutics (GALT) stake by 4.4% in Q1 2026, selling an estimated $10.4K and leaving 74,728 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #1093.

Hudson Bay Capital Management first reported a position in GALT in Q3 2025 and has held it in 3 quarters since. The position peaked at $325K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Hudson Bay Capital Management held 74,728 shares of Galectin Therapeutics worth $208K as of Q1 2026.
  • Hudson Bay Capital Management sold 3,417 Galectin Therapeutics shares in Q1 2026, an estimated $10.4K.
  • Galectin Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1093 holding.
  • Hudson Bay Capital Management first reported a position in Galectin Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Hudson Bay Capital Management's Galectin Therapeutics position peaked at $325K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.